Editas Medicine, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $394.7M
- Price
- $2.57
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.78%
- Volume
- 1.7M
About
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Quick stats
Shares outstanding153.6M
Computed float148.8M
Float / shares96.9%
Cash runway (months)16.9
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001650664
AI Summary
AI-generated1/32
minorneutralother
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
Editas Medicine announced two poster presentations at the ESGCT 33rd Annual Congress, held October 27-30, 2026, in Hamburg, Germany.
The posters cover targeted LNP delivery for in vivo CAR-T cell generation and a GMP-ready manufacturing platform for targeted LNP therapeutics, both presented by Harry An on October 28.
Management will also participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 10, 2026.